Programação
Filtrar atividades
Plenária
- 11:45 - 12:45 Módulo
-
Módulo Câncer de Pele e Sarcomas
-
RODRIGO MUNHOZ SP
Moderador
- 11:45 - 11:52
-
9506
Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic Merkel cell carcinoma - CheckMate358-
ANDREIA MELO RJ
Palestrante
-
- 11:52 - 12:00
-
LBA9503
Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.-
ANDREIA MELO RJ
Palestrante
-
- 12:00 - 12:07
-
LBA9505
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.-
IURI AMORIM DE SANTANA BA
Palestrante
-
- 12:07 - 12:15
-
101
The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.-
IURI AMORIM DE SANTANA BA
Palestrante
-
- 12:15 - 12:22
-
11503
A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).-
ROBERTO PESTANA SP
Palestrante
-
- 12:22 - 12:30
-
11524
Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.-
ROBERTO PESTANA SP
Palestrante
-
- 12:30 - 12:45
-
Discussão
-